<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3835">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056989</url>
  </required_header>
  <id_info>
    <org_study_id>SPX-101-CF-102</org_study_id>
    <nct_id>NCT03056989</nct_id>
  </id_info>
  <brief_title>A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis</brief_title>
  <official_title>A Phase 1, Single-Center, Open-Label Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spyryx Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spyryx Biosciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult
      subjects with cystic fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Day 1 through Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change from baseline through Day 8 in percent predicted FEV1</measure>
    <time_frame>Screening and Day 1 through Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline through Day 8 in clinical laboratory tests</measure>
    <time_frame>Screening and Day 1 through Day 8</time_frame>
    <description>Chemistry, Hematology, Urinalysis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>SPX-101 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation Solution twice daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPX-101 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation Solution twice daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPX-101 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation Solution twice daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPX-101</intervention_name>
    <description>Inhalation solution twice daily for 7 days.</description>
    <arm_group_label>SPX-101 Low Dose</arm_group_label>
    <arm_group_label>SPX-101 Mid Dose</arm_group_label>
    <arm_group_label>SPX-101 High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF

          -  FEV1 â‰¥ 40% predicted normal

          -  Stable CF lung disease

          -  Non-pregnant, non-lactating females

        Exclusion Criteria:

          -  Significant unstable co-morbidities within 28 days of screening as judged by the
             Investigator.

          -  Has received an investigational drug within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Tullis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alistair Wheeler, MD</last_name>
    <phone>919-899-9399</phone>
    <email>contact@spyryxbio.com</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>February 15, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
